IRONWOOD PHARMACEUTICALS INC Cash Flow Statement
IRWD / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
IRONWOOD PHARMACEUTICALS INC generated $127M in operating cash flow and $127M in free cash flow in FY2025. Free cash flow margin was 42.9% of revenue.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -2.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $24.0M | $175.1M | -$1.0B | $106.2M | $528.4M | -$282.4M | $21.5M | -$81.7M | -$116.9M | -$81.7M | -$142.7M | - | - | -$72.6M | -$64.9M |
| Depreciation & Amortization | $1.1M | $1.4M | $1.2M | $2.3M | $1.5M | $3.9M | $5.6M | $10.3M | $6.4M | $10.3M | $11.6M | $12.3M | $10.0M | $11.3M | $10.0M |
| Operating Cash Flow | $127.0M | $273.8M | $183.4M | $168.8M | $261.9M | -$70.9M | $10.7M | -$25.9M | -$100.8M | -$25.9M | -$106.9M | -$155.6M | -$75.2M | -$69.6M | -$75.2M |
| Capital Expenditures | $34.0K | $136.0K | $273.0K | $1.8M | $265.0K | $351.0K | $7.2M | $4.2M | $2.8M | $4.2M | $4.0M | $3.5M | $9.7M | $14.0M | $9.7M |
| Free Cash Flow | $127.0M | $273.6M | $183.2M | $167.0M | $261.6M | -$71.2M | $3.5M | -$30.1M | -$103.6M | -$30.1M | -$111.0M | -$159.1M | -$84.9M | -$83.6M | -$84.9M |
| Share Buybacks | - | $126.4M | - | $24.1M | $24.1M | - | - | - | - | - | - | - | - | - | - |
| FCF Margin | 42.9% | 66.6% | 41.4% | 42.9% | 63.2% | -20.5% | 0.8% | -11.0% | -198.5% | -11.0% | -74.2% | -208.2% | -128.9% | -55.6% | -128.9% |